In Brief: Circon/U.S. Surgical
This article was originally published in The Gray Sheet
Executive SummaryCircon/U.S. Surgical: Circon board reappoints President and CEO Richard Auhll to its board of directors. Auhll, who was also reappointed chairman, was ousted by an Oct. 6 shareholder vote which installed two USSC-nominated directors ("The Gray Sheet" Oct. 20, In Brief). USSC's hostile $16.50-per-share bid to acquire Circon, which was rejected in August and previously slated to expire Nov. 25, has been extended to Jan. 15, 1998. Auhll replaces Rudolf Schulte, board member since 1977, who resigned for "health and other personal reasons," Circon states. USSC has filed suit in Delaware chancery court seeking to nullify Auhll's reinstatement ("The Gray Sheet" Sept. 22, In Brief)...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.